Reimbursement recommendation
Colin Kerr
Published: Saturday, February 1, 2020
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. has announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee released a reimbursement recommendation for Verkazia TM (cyclosporine 0.1%) eyedrops.
“This recommendation marks an important step towards providing patients access to this new formulation of cyclosporine eye drops in Canada. Provincial jurisdictions are the final decision makers on public reimbursement,” said a Santen spokeswoman.
www.santen.com
Tags: industry, santen
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Picture This: Photo Contest Winners
ESCRS 2025 Refractive and Cataract Photo Contest winners.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.